Phase 2 trial of NTC-942 in patients with mild cognitive impairment
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2017
At a glance
- Drugs PRX 3140 (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- Sponsors Ology Bioservices
- 02 Oct 2017 According to a Ology Bioservices media release, Nanotherapeutics changed its name to Ology Bioservices.
- 22 Feb 2016 According to Nanotherapeutics website (http://www.nanotherapeutics.com/prx-3140/), company has plan to initiate this trial by late 2015 with completion set in 2016.
- 22 Feb 2016 New trial record